US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
WO1994011026A2
(en)
|
1992-11-13 |
1994-05-26 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
US6497878B1
(en)
|
1996-04-23 |
2002-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
|
WO1998013388A1
(fr)
|
1996-09-26 |
1998-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps contre les peptides lies a la parathormone humaine
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US5830698A
(en)
*
|
1997-03-14 |
1998-11-03 |
Idec Pharmaceuticals Corporation |
Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
|
AU737155B2
(en)
*
|
1997-03-14 |
2001-08-09 |
Biogen Idec Inc. |
Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
|
EP2322216A1
(en)
|
1997-03-21 |
2011-05-18 |
Chugai Seiyaku Kabushiki Kaisha |
A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
|
AU750021C
(en)
|
1997-05-15 |
2003-10-16 |
Chugai Seiyaku Kabushiki Kaisha |
Cachexia remedy
|
ES2308809T3
(es)
|
1997-08-15 |
2008-12-01 |
Chugai Seiyaku Kabushiki Kaisha |
Agentes preventivos y/o remedios que contienen anticuerpos neutralizantes antireceptores de il-6 para reducir la excrecion de la proteina urinaria en el lupus eritematoso sistemico.
|
JP4229475B2
(ja)
|
1997-10-03 |
2009-02-25 |
潤 藤田 |
ガンキリン
|
US6677436B1
(en)
|
1998-04-03 |
2004-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
|
EP1974747B1
(en)
*
|
1998-08-11 |
2012-06-27 |
Biogen Idec Inc. |
Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
|
MXPA01004648A
(es)
*
|
1998-11-09 |
2002-05-06 |
Idec Pharma Corp |
Tratamientro de enfermedades hematologicas malignas asociadas con celulas tumorales de la circulacion usando el anticuerpo quimerico anti-cd20.
|
MXPA01004649A
(es)
*
|
1998-11-09 |
2002-05-06 |
Idec Pharma Corp |
Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
|
AU2487300A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
ATE311199T1
(de)
*
|
1999-05-07 |
2005-12-15 |
Genentech Inc |
Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
|
TWI255718B
(en)
|
1999-07-02 |
2006-06-01 |
Chugai Pharmaceutical Co Ltd |
Ameliorative agent for low vasopressin concentration
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
KR20020025990A
(ko)
|
1999-08-23 |
2002-04-04 |
나가야마 오사무 |
에이치엠1.24 항원의 발현 증강제
|
DE60045638D1
(de)
|
1999-10-01 |
2011-03-31 |
Chugai Pharmaceutical Co Ltd |
Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
|
EP2278022A3
(en)
*
|
1999-11-01 |
2011-05-18 |
Novartis Vaccines and Diagnostics, Inc. |
Expression vectors, transfection systems, and method of use thereof
|
US6508714B1
(en)
*
|
1999-11-01 |
2003-01-21 |
Kop Flex, Inc. |
Split spool type flexible coupling
|
WO2001051646A2
(en)
*
|
2000-01-13 |
2001-07-19 |
Novozymes Biotech, Inc. |
Methods for producing a polypeptide using a crippled translational initiator sequence
|
JP4846169B2
(ja)
|
2000-04-28 |
2011-12-28 |
中外製薬株式会社 |
細胞増殖抑制剤
|
AU7373801A
(en)
*
|
2000-06-13 |
2001-12-24 |
Univ Queensland |
Expression modulating sequences
|
WO2002022212A2
(en)
*
|
2000-09-18 |
2002-03-21 |
Idec Pharmaceuticals Corporation |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
WO2002052005A1
(fr)
|
2000-12-22 |
2002-07-04 |
Kazusa Dna Research Institute Foundation |
Genes et proteines codees par ceux-ci
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
US6972324B2
(en)
*
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
US7211659B2
(en)
|
2001-07-05 |
2007-05-01 |
Chiron Corporation |
Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
|
DE60230918D1
(de)
|
2001-11-16 |
2009-03-05 |
Biogen Idec Inc |
Polycistronische expression von antikörpern in cho zellen
|
WO2003070956A1
(en)
*
|
2002-02-19 |
2003-08-28 |
Novozymes A/S |
Expression cloning methods in filamentous fungi
|
WO2004022595A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
MRL/lprマウスを用いた抗体の作製
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
DE60312039T2
(de)
*
|
2002-12-20 |
2007-11-08 |
Chromagenics B.V. |
Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
|
KR20050102627A
(ko)
*
|
2003-01-27 |
2005-10-26 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Igsf9 및 liv-1을 사용한 암 치료용 조성물 및치료방법
|
US7050173B2
(en)
*
|
2003-04-01 |
2006-05-23 |
Seagate Technology Llc |
Method and arrangement for removing noise and measurements of head-media spacing modulation for digital recording
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
JP4643450B2
(ja)
|
2003-08-08 |
2011-03-02 |
株式会社ペルセウスプロテオミクス |
癌高発現遺伝子
|
EP1660654B1
(en)
*
|
2003-09-04 |
2011-11-09 |
Medarex, Inc. |
Expression vector
|
CN1914320A
(zh)
|
2003-12-03 |
2007-02-14 |
中外制药株式会社 |
利用哺乳类β肌动蛋白启动子的表达体系
|
EP1710255A4
(en)
|
2003-12-12 |
2008-09-24 |
Chugai Pharmaceutical Co Ltd |
MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
|
EP1728801A4
(en)
|
2004-03-24 |
2009-10-21 |
Chugai Pharmaceutical Co Ltd |
SUBTYP OF A HUMANIZED ANTIBODY AGAINST THE INTERLEUKIN-6 RECEPTOR
|
ES2353967T3
(es)
|
2004-07-09 |
2011-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-glipicano 3 .
|
US8039230B2
(en)
*
|
2004-11-08 |
2011-10-18 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
US8999667B2
(en)
*
|
2004-11-08 |
2015-04-07 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
PL1809750T3
(pl)
*
|
2004-11-08 |
2012-08-31 |
Chromagenics Bv |
Selekcja komórki gospodarza eksprymującej białko na wysokich poziomach
|
US20060172382A1
(en)
*
|
2004-11-08 |
2006-08-03 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
US20060195935A1
(en)
*
|
2004-11-08 |
2006-08-31 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
CN101330929B
(zh)
|
2005-10-14 |
2014-03-05 |
学校法人福冈大学 |
胰岛移植中的移植胰岛障碍抑制剂
|
EP1941908B1
(en)
|
2005-10-21 |
2015-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for heart disease
|
EP1964574B1
(en)
|
2005-11-14 |
2016-09-07 |
Cellmid Limited |
Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
WO2007061029A1
(ja)
|
2005-11-25 |
2007-05-31 |
Keio University |
前立腺癌治療剤
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
JP5033643B2
(ja)
|
2006-01-27 |
2012-09-26 |
学校法人慶應義塾 |
脈絡膜血管新生を伴う疾患の治療剤
|
PL1987150T3
(pl)
*
|
2006-02-21 |
2011-10-31 |
Chromagenics Bv |
Selekcja komórek gospodarza wyrażających białka na wysokim poziomach
|
CA2648644C
(en)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Muscle regeneration promoter
|
US20090220524A1
(en)
|
2006-04-25 |
2009-09-03 |
The University Of Tokyo |
Therapeutic agents for alzheimer's disease and cancer
|
MX2008015975A
(es)
|
2006-06-14 |
2009-03-26 |
Chugai Pharmaceutical Co Ltd |
Agentes para promocionar el crecimiento de celulas de vastago hematopoyeticas.
|
KR101351208B1
(ko)
|
2006-06-21 |
2014-01-14 |
온코세라피 사이언스 가부시키가이샤 |
Fzd10에 대한 종양-표적화 모노클로날 항체 및 이의 용도
|
EP2050466B1
(en)
|
2006-08-14 |
2015-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
NZ601022A
(en)
|
2006-10-12 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Diagnosis and treatment of cancer using anti-ereg antibody
|
EP3040347A3
(en)
|
2006-10-20 |
2016-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
EP2093237B1
(en)
|
2006-10-20 |
2015-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
|
WO2008072723A1
(ja)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
|
WO2008081942A1
(ja)
|
2007-01-05 |
2008-07-10 |
The University Of Tokyo |
抗prg-3抗体を用いる癌の診断および治療
|
JP5254807B2
(ja)
|
2007-01-23 |
2013-08-07 |
国立大学法人信州大学 |
慢性拒絶反応抑制剤
|
CA2679266A1
(en)
|
2007-02-27 |
2008-09-04 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
WO2008138835A1
(en)
|
2007-05-09 |
2008-11-20 |
Novozymes A/S |
Expression cloning method suitable for selecting library clones producing a polypeptide of interest
|
US8722858B2
(en)
|
2007-06-25 |
2014-05-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-Prominin-1 antibody having ADCC activity or CDC activity
|
EP3246045A1
(en)
|
2007-07-26 |
2017-11-22 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
KR101601986B1
(ko)
|
2007-10-02 |
2016-03-17 |
추가이 세이야쿠 가부시키가이샤 |
인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
|
CA2705509A1
(en)
|
2007-11-14 |
2009-05-22 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-gpr49 antibody
|
PE20091024A1
(es)
|
2007-11-15 |
2009-08-12 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos monoclonales que se unen a anexelekto y sus usos
|
EP2241333A1
(en)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
ES2426093T3
(es)
|
2008-01-10 |
2013-10-21 |
Shionogi & Co., Ltd. |
Anticuerpo dirigido contra PcrV
|
RU2010133547A
(ru)
|
2008-01-11 |
2012-02-20 |
Дзе Юниверсити Оф Токио (Jp) |
Анти-cldn антитела
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
CN102256623A
(zh)
|
2008-06-05 |
2011-11-23 |
独立行政法人国立癌症研究中心 |
神经浸润抑制剂
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
US9435811B2
(en)
|
2008-09-30 |
2016-09-06 |
Oriental Yeast Co., Ltd |
Inducer of chondrocyte proliferation and differentiation
|
EP2351777B1
(en)
|
2008-10-28 |
2015-10-28 |
Shionogi&Co., Ltd. |
Anti-muc1 antibody
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
EP2388320B1
(en)
|
2008-12-22 |
2017-02-15 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-hs6st2 antibodies and uses thereof
|
CN102325881B
(zh)
|
2008-12-22 |
2014-08-20 |
国立大学法人北海道大学 |
用于用动物细胞大量生产源自外源基因的蛋白质的表达载体及其应用
|
EP2385114A4
(en)
|
2008-12-25 |
2012-08-08 |
Univ Tokyo |
CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
|
EP2377891B1
(en)
|
2008-12-26 |
2018-11-21 |
The University of Tokyo |
Diagnosis and treatment of cancer using anti-lgr7 antibody
|
EP2392352B1
(en)
|
2009-01-28 |
2017-10-25 |
Korea Research Institute of Bioscience and Biotechnology |
Cd93 or use of soluble fragment thereof
|
EP2420515A4
(en)
|
2009-04-16 |
2013-08-28 |
Univ Tokyo |
DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY
|
JP5808052B2
(ja)
|
2009-05-29 |
2015-11-10 |
中外製薬株式会社 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
EP2460538B1
(en)
|
2009-07-31 |
2017-09-13 |
Shin Maeda |
Cancer metastasis inhibitor
|
WO2011021381A1
(ja)
|
2009-08-17 |
2011-02-24 |
株式会社未来創薬研究所 |
抗hb-egf抗体を有効成分として含む医薬組成物
|
CN102482348B
(zh)
|
2009-09-16 |
2014-08-27 |
盐野义制药株式会社 |
胶原新表位抗体
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
JP5728718B2
(ja)
|
2009-12-28 |
2015-06-03 |
オンコセラピー・サイエンス株式会社 |
抗cdh3抗体およびその使用
|
DK2530091T3
(en)
|
2010-01-29 |
2018-05-28 |
Chugai Pharmaceutical Co Ltd |
ANTI-DLL3 ANTIBODY
|
US9173961B2
(en)
|
2010-02-10 |
2015-11-03 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
EP2540827A4
(en)
|
2010-02-26 |
2013-09-04 |
Chugai Pharmaceutical Co Ltd |
ANTI-ICAM3 ANTIBODIES AND USE THEREOF
|
JP5904552B2
(ja)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
膵癌治療剤
|
PT2578231T
(pt)
|
2010-05-28 |
2022-12-02 |
Chugai Pharmaceutical Co Ltd |
Potenciador de resposta de células t antitumoral
|
WO2012005076A1
(ja)
|
2010-07-08 |
2012-01-12 |
本田技研工業株式会社 |
高周波加熱用コイル
|
JP6030452B2
(ja)
|
2010-11-30 |
2016-11-24 |
中外製薬株式会社 |
複数分子の抗原に繰り返し結合する抗原結合分子
|
TWI807362B
(zh)
|
2010-11-30 |
2023-07-01 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
EP2698431B1
(en)
|
2011-03-30 |
2020-09-09 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
JPWO2012133914A1
(ja)
|
2011-03-31 |
2014-07-28 |
オリエンタル酵母工業株式会社 |
Ranklアンタゴニストを含む癌免疫増強剤
|
EP2700652B1
(en)
|
2011-04-18 |
2018-12-19 |
The University of Tokyo |
Diagnosis and treatment of cancer using anti-itm2a antibody
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
WO2013017691A1
(en)
|
2011-08-04 |
2013-02-07 |
Medizinische Universität Innsbruck |
Cahgt1p inhibitors for use in the treatment of candidiasis
|
WO2013027802A1
(ja)
|
2011-08-23 |
2013-02-28 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
WO2013035824A1
(ja)
|
2011-09-07 |
2013-03-14 |
ファーマロジカルズ・リサーチ プライベート リミテッド |
癌幹細胞の分離
|
CN110627902A
(zh)
|
2011-09-30 |
2019-12-31 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
CN110639014A
(zh)
|
2011-09-30 |
2020-01-03 |
中外制药株式会社 |
促进抗原消除的抗原结合分子
|
JP6284766B2
(ja)
|
2011-09-30 |
2018-02-28 |
中外製薬株式会社 |
イオン濃度依存性結合分子ライブラリ
|
JP6271251B2
(ja)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
WO2013062083A1
(ja)
|
2011-10-28 |
2013-05-02 |
ファーマロジカルズ・リサーチ プライベート リミテッド |
癌幹細胞特異的分子
|
BR112014013081A2
(pt)
|
2011-11-30 |
2020-10-20 |
Chugai Seiyaku Kabushiki Kaisha |
veículo contendo fármaco em célula para formação de um complexo imune
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
US9222947B2
(en)
|
2012-02-03 |
2015-12-29 |
Shionogi & Co., Ltd. |
Anti-sAPPβ antibody
|
TW202231872A
(zh)
|
2012-02-24 |
2022-08-16 |
日商中外製藥股份有限公司 |
經FcγRIIB促進抗原消失之抗原結合分子
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
US9416189B2
(en)
|
2012-05-11 |
2016-08-16 |
Microbial Chemistry Research Foundation |
Anti-CXADR antibody
|
US20150166654A1
(en)
|
2012-05-30 |
2015-06-18 |
Chugai Seiyaku Kabushiki Kaisha |
Target tissue-specific antigen-binding molecule
|
DK2857419T3
(da)
|
2012-05-30 |
2021-03-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-bindende molekyle til eliminering af aggregerede antigener
|
EP2881467B1
(en)
|
2012-07-30 |
2018-10-31 |
National University Corporation Nagoya University |
Monoclonal antibody against human midkine
|
EP2722341B1
(en)
|
2012-10-22 |
2017-12-06 |
Fountain Biopharma Inc. |
Antibodies to interleukin-6 and uses thereof
|
WO2015097928A1
(ja)
|
2013-12-24 |
2015-07-02 |
中外製薬株式会社 |
可溶性gpc3タンパク質の測定方法
|
JP6357113B2
(ja)
|
2013-02-08 |
2018-07-11 |
株式会社医学生物学研究所 |
ヒトnrg1タンパク質に対する抗体
|
JP6490574B2
(ja)
|
2013-02-28 |
2019-03-27 |
国立研究開発法人国立がん研究センター |
不溶性フィブリンに対する抗体
|
CA2905597C
(en)
|
2013-03-14 |
2019-09-24 |
Shionogi & Co., Ltd. |
Monoclonal antibody inhibiting enzymatic activity of endothelial lipase
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
TW201542591A
(zh)
|
2013-06-24 |
2015-11-16 |
Chugai Pharmaceutical Co Ltd |
含有以人源化抗Epiregulin抗體爲有效成分的腺癌以外的非小細胞肺癌之治療劑
|
WO2015005473A1
(ja)
|
2013-07-12 |
2015-01-15 |
独立行政法人国立がん研究センター |
がんの治療への応答性を予測する方法
|
US20160229922A1
(en)
|
2013-09-20 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
EP3070167A4
(en)
|
2013-11-06 |
2017-06-07 |
Osaka University |
Antibody having broad neutralizing activity in group 1 influenza a virus
|
JP7060317B2
(ja)
|
2013-12-04 |
2022-04-26 |
中外製薬株式会社 |
化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
|
AU2014370883B2
(en)
|
2013-12-26 |
2020-09-24 |
Mitsubishi Tanabe Pharma Corporation |
Human anti-IL-33 neutralizing monoclonal antibody
|
KR20180095740A
(ko)
|
2015-02-27 |
2018-08-27 |
추가이 세이야쿠 가부시키가이샤 |
Il-6 관련 질환 치료용 조성물
|
IL309289A
(en)
|
2015-10-09 |
2024-02-01 |
Genzyme Corp |
Improved combustion technology (flow cytometry that reduces the expression of the reporter) for rapid sorting of substances in high masses
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
EP3378487B1
(en)
|
2015-11-18 |
2022-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
|
RU2746754C2
(ru)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
|
JP7094557B2
(ja)
|
2016-08-31 |
2022-07-04 |
オンコセラピー・サイエンス株式会社 |
Melkに対するモノクローナル抗体およびその使用
|
TWI762516B
(zh)
|
2016-10-06 |
2022-05-01 |
日商腫瘤療法 科學股份有限公司 |
針對fzd10之單株抗體及其用途
|
TW202346598A
(zh)
|
2016-10-07 |
2023-12-01 |
美商健臻公司 |
用於生物製劑生產之細胞早期轉染後分離(epic)
|
DK3616720T3
(da)
|
2017-03-29 |
2021-03-29 |
Shionogi & Co |
Farmaceutisk sammensætning til cancerbehandling
|
JP7185884B2
(ja)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
CA3074421A1
(en)
|
2017-08-31 |
2019-02-07 |
Mitsubishi Tanabe Pharma Corporation |
Il-33 antagonist-containing therapeutic agent for endometriosis
|
KR20200074160A
(ko)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
TWI822728B
(zh)
|
2018-01-31 |
2023-11-21 |
加藤元一 |
含有il-6抑制劑的哮喘治療劑
|
US20230038521A1
(en)
|
2018-09-21 |
2023-02-09 |
National University Corporation Tokyo Medical An D Dental University |
Human Monoclonal Antibody Binding Specifically to Human Hmgb1, and Pharmaceutical Composition for Treating or Preventing Alzheimer's Disease Containing Said Human Monoclonal Antibody
|
EP3915581A4
(en)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS
|
CN113613676A
(zh)
|
2019-03-19 |
2021-11-05 |
中外制药株式会社 |
包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
|
US20220204608A1
(en)
|
2019-04-17 |
2022-06-30 |
Hiroshima University |
Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
|
MX2021014433A
(es)
|
2019-06-05 |
2022-03-11 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a sitio de escision de anticuerpo.
|
EP4063507A4
(en)
|
2019-11-21 |
2024-04-17 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PREDICTING THE SENSITIVITY OF CANCER CELLS TO A HELICASE INHIBITOR
|
EP4082575A4
(en)
|
2019-12-26 |
2024-01-31 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PREDICTING THE SENSITIVITY OF CANCER CELLS TO GPX4 INHIBITORS
|
WO2021193763A1
(ja)
|
2020-03-25 |
2021-09-30 |
富士レビオ株式会社 |
ヒトiv型コラーゲン7sドメインを含む断片の測定方法及びこれに用いるためのキット
|
CN115348971A
(zh)
|
2020-03-30 |
2022-11-15 |
国立研究开发法人国立癌症研究中心 |
抗体-药物缀合物
|
MX2023001120A
(es)
|
2020-07-31 |
2023-02-22 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.
|
EP4260872A1
(en)
|
2020-12-09 |
2023-10-18 |
National University Corporation Tokyo Medical and Dental University |
Agent for preventing or treating frontotemporal lobar degeneration
|
KR20230126221A
(ko)
|
2021-01-14 |
2023-08-29 |
고쿠리츠다이가쿠호진 니이가타 다이가쿠 |
네프로제 증후군의 진단을 보조하기 위한 마커 및 그사용
|
JP7289857B2
(ja)
|
2021-02-08 |
2023-06-12 |
プライムプラネットエナジー&ソリューションズ株式会社 |
正極活物質混合物の製造方法および検査方法
|
JPWO2022191306A1
(ko)
|
2021-03-12 |
2022-09-15 |
|
|